Literature DB >> 21946843

Resistance: Cetuximab's tip to become irresistible.

M Teresa Villanueva.   

Abstract

Entities:  

Year:  2011        PMID： 21946843     DOI： 10.1038/nrclinonc.2011.145

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.

Authors:  Kimio Yonesaka; Kreshnik Zejnullahu; Isamu Okamoto; Taroh Satoh; Federico Cappuzzo; John Souglakos; Dalia Ercan; Andrew Rogers; Massimo Roncalli; Masayuki Takeda; Yasuhito Fujisaka; Juliet Philips; Toshio Shimizu; Osamu Maenishi; Yonggon Cho; Jason Sun; Annarita Destro; Koichi Taira; Koji Takeda; Takafumi Okabe; Jeffrey Swanson; Hiroyuki Itoh; Minoru Takada; Eugene Lifshits; Kiyotaka Okuno; Jeffrey A Engelman; Ramesh A Shivdasani; Kazuto Nishio; Masahiro Fukuoka; Marileila Varella-Garcia; Kazuhiko Nakagawa; Pasi A Jänne
Journal:  Sci Transl Med       Date:  2011-09-07       Impact factor: 17.956
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.